261 related articles for article (PubMed ID: 31392195)
1. Long-term outcome and unmet needs in infantile-onset Pompe disease.
Hahn A; Schänzer A
Ann Transl Med; 2019 Jul; 7(13):283. PubMed ID: 31392195
[TBL] [Abstract][Full Text] [Related]
2. Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state.
Matsuoka T; Miwa Y; Tajika M; Sawada M; Fujimaki K; Soga T; Tomita H; Uemura S; Nishino I; Fukuda T; Sugie H; Kosuga M; Okuyama T; Umeda Y
Mol Genet Metab Rep; 2016 Dec; 9():98-105. PubMed ID: 27896132
[TBL] [Abstract][Full Text] [Related]
3. Genotype, phenotype and treatment outcomes of 17 Malaysian patients with infantile-onset Pompe disease and the identification of 3 novel GAA variants.
Chan MY; Jalil JA; Yakob Y; Wahab SAA; Ali EZ; Khalid MKNM; Leong HY; Chew HB; Sivabalakrishnan JB; Ngu LH
Orphanet J Rare Dis; 2023 Aug; 18(1):231. PubMed ID: 37542277
[TBL] [Abstract][Full Text] [Related]
4. The phenotype, genotype, and outcome of infantile-onset Pompe disease in 18 Saudi patients.
Al-Hassnan ZN; Khalifa OA; Bubshait DK; Tulbah S; Alkorashy M; Alzaidan H; Alowain M; Rahbeeni Z; Al-Sayed M
Mol Genet Metab Rep; 2018 Jun; 15():50-54. PubMed ID: 30023291
[TBL] [Abstract][Full Text] [Related]
5. Newborn screening for Pompe disease in Italy: Long-term results and future challenges.
Gragnaniello V; Pijnappel PWWM; Burlina AP; In 't Groen SLM; Gueraldi D; Cazzorla C; Maines E; Polo G; Salviati L; Di Salvo G; Burlina AB
Mol Genet Metab Rep; 2022 Dec; 33():100929. PubMed ID: 36310651
[TBL] [Abstract][Full Text] [Related]
6. A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation.
Curelaru S; Desai AK; Fink D; Zehavi Y; Kishnani PS; Spiegel R
Mol Genet Metab Rep; 2022 Sep; 32():100893. PubMed ID: 35813979
[TBL] [Abstract][Full Text] [Related]
7. Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences.
Chien YH; Tsai WH; Chang CL; Chiu PC; Chou YY; Tsai FJ; Wong SL; Lee NC; Hwu WL
Mol Genet Metab Rep; 2020 Jun; 23():100591. PubMed ID: 32373469
[TBL] [Abstract][Full Text] [Related]
8. A New Mutation Causing Severe Infantile-Onset Pompe Disease Responsive to Enzyme Replacement Therapy.
Moravej H; Amirhakimi A; Showraki A; Amoozgar H; Hadipour Z; Nikfar G
Iran J Med Sci; 2018 Mar; 43(2):218-222. PubMed ID: 29749992
[TBL] [Abstract][Full Text] [Related]
9. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.
Parini R; De Lorenzo P; Dardis A; Burlina A; Cassio A; Cavarzere P; Concolino D; Della Casa R; Deodato F; Donati MA; Fiumara A; Gasperini S; Menni F; Pagliardini V; Sacchini M; Spada M; Taurisano R; Valsecchi MG; Di Rocco M; Bembi B
Orphanet J Rare Dis; 2018 Feb; 13(1):32. PubMed ID: 29422078
[TBL] [Abstract][Full Text] [Related]
10. The Outcome of Infantile Onset Pompe Disease in South of Iran.
Moravej H; Karamizadeh Z; Paran M
Iran J Pediatr; 2016 Feb; 26(1):e4473. PubMed ID: 26848380
[TBL] [Abstract][Full Text] [Related]
11. Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease.
Chien YH; Hwu WL; Lee NC; Tsai FJ; Koeberl DD; Tsai WH; Chiu PC; Chang CL
Mol Genet Metab Rep; 2017 Jun; 11():31-35. PubMed ID: 28480166
[TBL] [Abstract][Full Text] [Related]
12. Expert Group Consensus on early diagnosis and management of infantile-onset pompe disease in the Gulf Region.
Al-Hassnan Z; Hashmi NA; Makhseed N; Omran TB; Al Jasmi F; Teneiji AA
Orphanet J Rare Dis; 2022 Oct; 17(1):388. PubMed ID: 36303251
[TBL] [Abstract][Full Text] [Related]
13. The humanistic burden of Pompe disease: are there still unmet needs? A systematic review.
Schoser B; Bilder DA; Dimmock D; Gupta D; James ES; Prasad S
BMC Neurol; 2017 Nov; 17(1):202. PubMed ID: 29166883
[TBL] [Abstract][Full Text] [Related]
14. Multicentric Retrospective Evaluation of Five Classic Infantile Pompe Disease Subjects Under Enzyme Replacement Therapy With Early Infratentorial Involvement.
Paoletti M; Pichiecchio A; Colafati GS; Conte G; Deodato F; Gasperini S; Menni F; Furlan F; Rubert L; Triulzi FM; Cinnante C
Front Neurol; 2020; 11():569153. PubMed ID: 33329311
[TBL] [Abstract][Full Text] [Related]
15. Atypical infantile-onset Pompe disease with good prognosis from mainland China: A case report.
Zhang Y; Zhang C; Shu JB; Zhang F
World J Clin Cases; 2022 Apr; 10(10):3278-3283. PubMed ID: 35603335
[TBL] [Abstract][Full Text] [Related]
16. A Liver Model of Infantile-Onset Pompe Disease Using Patient-Specific Induced Pluripotent Stem Cells.
Yoshida T; Jonouchi T; Osafune K; Takita J; Sakurai H
Front Cell Dev Biol; 2019; 7():316. PubMed ID: 31850350
[TBL] [Abstract][Full Text] [Related]
17. Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy.
Hsueh CY; Huang CY; Yang CF; Chang CC; Lin WS; Cheng HL; Wu SL; Cheng YF; Niu DM
Orphanet J Rare Dis; 2021 Aug; 16(1):348. PubMed ID: 34353347
[TBL] [Abstract][Full Text] [Related]
18. Gene Therapy for Pompe Disease: The Time is now.
Colella P; Mingozzi F
Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
[TBL] [Abstract][Full Text] [Related]
19. A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan.
Fukuhara Y; Fuji N; Yamazaki N; Hirakiyama A; Kamioka T; Seo JH; Mashima R; Kosuga M; Okuyama T
Mol Genet Metab Rep; 2018 Mar; 14():3-9. PubMed ID: 29124014
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
